Avalo Therapeutics, Inc. (NASDAQ:AVTX) Short Interest Update

Avalo Therapeutics, Inc. (NASDAQ:AVTX - Get Free Report) was the recipient of a large decrease in short interest in the month of January. As of January 15th, there was short interest totalling 20,200 shares, a decrease of 11.8% from the December 31st total of 22,900 shares. Based on an average daily volume of 84,800 shares, the short-interest ratio is currently 0.2 days. Approximately 0.2% of the shares of the company are short sold.

Analyst Ratings Changes

A number of equities research analysts have weighed in on AVTX shares. HC Wainwright started coverage on shares of Avalo Therapeutics in a research note on Thursday, October 24th. They set a "neutral" rating on the stock. BTIG Research started coverage on shares of Avalo Therapeutics in a research report on Thursday, December 19th. They issued a "buy" rating and a $40.00 price objective for the company.

Institutional Investors Weigh In On Avalo Therapeutics

An institutional investor recently bought a new position in Avalo Therapeutics stock. RA Capital Management L.P. bought a new position in shares of Avalo Therapeutics, Inc. (NASDAQ:AVTX - Free Report) during the 3rd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm bought 967,000 shares of the company's stock, valued at approximately $9,186,000. RA Capital Management L.P. owned 93.88% of Avalo Therapeutics at the end of the most recent quarter. 87.06% of the stock is currently owned by institutional investors and hedge funds.

Avalo Therapeutics Stock Performance

NASDAQ AVTX traded up $0.09 during trading hours on Tuesday, hitting $8.11. 40,052 shares of the company traded hands, compared to its average volume of 78,683. Avalo Therapeutics has a twelve month low of $4.01 and a twelve month high of $34.46. The business's 50-day moving average is $8.37 and its 200-day moving average is $9.73.

Avalo Therapeutics Company Profile

Avalo Therapeutics, Inc, a clinical stage biotechnology company, focuses on the development of therapies for the treatment of immune dysregulation in the Unites States. The company's drug candidates include AVTX-009, an Anti-IL-1ß monoclonal antibody which is under Phase I targeting inflammatory diseases; and AVTX-008, a fully human B and T lymphocyte attenuator agonist fusion protein for the treatment of immune dysregulation disorders.